We’re proud to celebrate the success of Dr. Richard DiMarchi and his team in advancing translational research from the lab bench to the clinic.
MBX Biosciences — co-founded on discoveries made at Indiana University — has now licensed three peptides discovered in Dr. DiMarchi’s IUB lab, each moving forward in clinical studies to treat three different diseases:
🔹 Canvuparatide (MBX 2109) – Phase 2 trial for chronic hypoparathyroidism, topline results expected Q3 2025.
🔹 Imapextide (MBX 1416) – Phase 2a trial for post-bariatric hypoglycemia, beginning Q3 2025.
🔹 MBX 4291 – Phase 1 trial for obesity, beginning Q3 2025.
With over $250M raised since its founding in 2018, MBX is driving innovation in precision peptide therapies — a testament to how IU research can lead to transformative health solutions.
Congratulations to Dr. DiMarchi and all involved for translating cutting-edge science into potential life-changing treatments!
